Antigenic carbohydrate linked to an immunogenic carrier
    1.
    发明授权
    Antigenic carbohydrate linked to an immunogenic carrier 有权
    与抗原性载体连接的抗原性碳水化合物

    公开(公告)号:US06165468A

    公开(公告)日:2000-12-26

    申请号:US147045

    申请日:1998-09-25

    申请人: Stefan Svenson

    发明人: Stefan Svenson

    摘要: A general method of producing an immunogenic product consisting of antigenically active carbohydrate moieties (ACM) which each are covalently coupled via identical divalent bridge groups to immunologically active carriers (IAC) containing amino groups, is disclosed. The immunogenic product comprises a divalent bridge group which has structural formula (I). In addition to the immunogenic product, the invention also comprises use of said product as immunizing component. ##STR1##

    摘要翻译: PCT No.PCT / EP97 / 01321 Sec。 371日期:1998年9月25日 102(e)1998年9月25日PCT 1997年3月17日PCT公布。 出版物WO97 / 35613 PCT 日期1997年10月2日公开了一种生产由抗原活性碳水化合物部分(ACM)组成的免疫原性产物的一般方法,它们各自通过相同的二价桥基团与含有氨基的免疫活性载体(IAC)共价连接。 免疫原性产物包含具有结构式(I)的二价桥基。 除免疫原性产物外,本发明还包括使用所述产品作为免疫组分。

    Purifying protein or peptide recombinant DNA products by
electroseparation
    2.
    发明授权
    Purifying protein or peptide recombinant DNA products by electroseparation 失效
    通过电离分离纯化蛋白质或肽重组DNA产物

    公开(公告)号:US4746647A

    公开(公告)日:1988-05-24

    申请号:US834336

    申请日:1986-03-14

    申请人: Stefan Svenson

    发明人: Stefan Svenson

    摘要: A method of purifying a contaminated product (protein/peptide) produced by rDNA technique, from hydrophobic contaminants which are charged and originate from the microbial cloning host employed, and the product thus purified are disclosed. The contaminated product is subjected to electroseparation, such as electrodialysis, to remove the contaminants. A charge-providing pretreatment is resorted to when the contaminants themselves are not charged enough to enable them to be directly separated upon electroseparation. In addition, a method of checking the purity of a product (protein/peptide) produced by rDNA technique is disclosed. Moreover, a method of checking the efficiency of the purification process used for purifying a product is disclosed.

    摘要翻译: PCT No.PCT / SE85 / 00218 Sec。 371日期:1986年3月27日 102(e)1986年3月14日PCT PCT。1985年5月24日PCT公布。 出版物WO85 / 05631 1985年12月19日的日期。一种通过rDNA技术产生的污染产物(蛋白质/肽)的纯化方法,其由来自所使用的微生物克隆宿主的来自疏水性污染物的疏水性污染物和如此纯化的产物进行了公开。 受污染的产品经过电分离,例如电渗析,以除去污染物。 当污染物本身没有充电足以使其能够在电分离时直接分离时,进行电荷提供预处理。 另外,公开了通过rDNA技术制备的产品(蛋白质/肽)的纯度检查方法。 此外,公开了一种检查用于净化产品的纯化过程效率的方法。

    Vaccine composition
    3.
    发明授权
    Vaccine composition 失效
    疫苗组成

    公开(公告)号:US06936260B1

    公开(公告)日:2005-08-30

    申请号:US09926001

    申请日:2000-02-09

    摘要: A tuberculosis (TB) vaccine composition is disclosed. The composition comprises, as adjuvant, one or more substances selected from a) monoglyceride preparations having at least 80% monoglyceride content and b) fatty acids of the general formula CH3—(CH2)n—COOH where “n” may be varied between 4 and 22, and where the acyl chain may contain one or more unsaturated bonds, and as immunizing component, inactivated, e.g. heat killed or formalin killed, Mycobacterium tuberculosis bacteria.

    摘要翻译: 公布了结核病(TB)疫苗组合物。 组合物包含一种或多种选自以下的物质:a)具有至少80%单酸甘油酯含量的单甘油酯制剂,和b)通式为CH 3 - (CH 2) 其中“n”可以在4和22之间变化,并且其中酰基链可以含有一个或多个不饱和键,并且作为免疫组分,灭活,例如 热杀死或福尔马林死亡,结核分枝杆菌细菌。

    Vaccine formulation
    4.
    发明授权
    Vaccine formulation 失效
    疫苗配方

    公开(公告)号:US06890540B1

    公开(公告)日:2005-05-10

    申请号:US09926002

    申请日:2000-02-09

    摘要: A vaccine formulation against a microorganism is disclosed. The formulation comprises: as adjuvant, one or more substances selected from a) monoglyceride preparations having at least 80% monoglyceride content and b) fatty acids of the general formula CH3—(CH2)n—COOH where “n” may be varied between 4 and 22, and where the acyl chain may contain one or more unsaturated bonds, and as immunizing component, an immunogenic product consisting of antigenically active carbohydrate moieties (ACM) derived from said microorganism which are each covalently coupled, possibly via identical divalent bridge groups, to immunologically active carriers (IAC). The vaccine formulation is e.g. against Mycobacterium tuberculosis and in that case the formulation may comprise, as adjuvant, a mixture of mono-olein and oleic acid, and possibly soybean oil, and, as immunizing component, lipoarabinomamman-tetanus toxoid (LAM-TT).

    摘要翻译: 公开了针对微生物的疫苗制剂。 制剂包含:作为佐剂,一种或多种选自以下的物质:a)具有至少80%单酸甘油酯含量的单甘油酯制剂,和b)通式CH 3 - (CH 2) 其中“n”可以在4和22之间变化,并且其中酰基链可以含有一个或多个不饱和键,并且作为免疫组分,由抗原性组成的免疫原性产物 衍生自所述微生物的活性碳水化合物部分(ACM)可以通过相同的二价桥基团共价偶联至免疫活性载体(IAC)。 疫苗制剂是例如。 针对结核分枝杆菌,并且在这种情况下,制剂可以包含作为佐剂的单油酸和油酸的混合物,以及可能的大豆油,以及作为免疫组分的脂质阿拉伯马斯曼破伤风类毒素(LAM-TT)。